Frequently Asked Questions

To receive a HelioLiver LDT kit, please fill out our kit order form and include the number of kits you would like to order. Our team will follow up with you for additional information.

The HelioLiver LDT requires 2 x 10 mL whole blood samples and 1 x 8.5 mL serum sample.

There are no requirements for taking the HelioLiver LDT.

Results will be available in 10–14 days.

An epigenomic blood test that reads cell-free DNA (cfDNA) methylation patterns alongside protein tumour markers to identify early-stage HCC.

The HelioLiver LDT is designed for patients at risk for HCC, such as those with cirrhosis. Risk factors for cirrhosis include chronic hepatitis B or hepatitis C, excessive alcohol use, and fatty liver disease (MASLD/NAFLD). Less-prevalent conditions, such as hereditary hemochromatosis, primary biliary cholangitis (PBC), and Wilson's disease, are also associated with HCC development.

An "abnormal" result indicates a higher likelihood that HCC is present in the patient's sample. Follow-up diagnostic imaging is recommended to confirm a diagnosis.

A "normal" result indicates that HCC was not detected in the patient's sample. A follow-up visit in 6 months is recommended.

According to AASLD Guidelines, abnormalities may be caused by something other than HCC, and further diagnostic testing is needed for confirmation.

The HelioLiver LDT checks for signs of liver cancer at the time of a blood draw and is recommended for patients at high risk. Given the nature of liver cancer, follow-up routine testing is recommended to ensure continual surveillance.

The HelioLiver LDT analyses the methylation patterns in the patient's sample against cancer-specific markers validated to indicate the presence of HCC. Cell-free DNA is DNA released into the blood circulation from both normal and cancer cells. cfDNA is also used in detecting Down syndrome and determining the sex and Rhesus (Rh) factor status of a fetus.

DNA methylation is a process cells use to control gene expression. To learn more about how Helio Genomics analyses cell-free methylation patterns in a patient's sample to detect cancer, watch this video.

Methylation patterns of cfDNA carry rich information about recent cell-death events in the body, which can include the earliest signs of cancer development. These patterns can be compared against cancer-specific DNA methylation markers to indicate the presence of cancer cells in the sample.

Rather than investigating one or a few genetic changes found only in cancer-derived DNA, we use artificial intelligence to examine the whole spectrum, length, variation, and position, to infer whether the pattern is cancerous.

All billing questions are handled directly by HelioLiver. HelioLiver's friendly and experienced staff will walk your patient through the billing process. For all questions about billing, please have your patient call (855) 864-3546 or info@heliogenomics.com.

We currently accept three different types of payment, including insurance, institutional billing, and patient self-pay.

For current pricing and payment options, please reach out to billing@helioliverLDT.com.

We accept all commercial and federal insurances and are in-network with most major commercial payers. For more information, please email billing@helioliverLDT.com.

We offer an affordable self-pay cash rate for those patients without insurance, and we'll work with patients so that cost is not a barrier to testing. For more information, please email info@heliogenomics.com.

We are committed to helping all patients get the care they need. Our Compassionate Care Program is made for patients who are uninsured or generally concerned about their ability to pay for the HelioLiver LDT. For more information about this program, please have your patient contact us directly at info@heliogenomics.com.

We know how sensitive your personal data is, which is why we treat it with the utmost care and responsibility. For more information about this and other privacy-related questions, please refer to our Privacy Policy.

HelioLiver never sells your personal information or data. We take your privacy very seriously. Under California's California Consumer Privacy Act ("CCPA"), effective as of January 1, 2020, California residents are given the right to opt out of the sale of their personal information.

While we do not sell any data of our customers, our website uses cookies. Cookies are used to improve user experience, track anonymous site usage, store authorization tokens, enhance usability, support marketing activities, and permit voluntary sharing on social media networks (please see our Privacy Policy for a full description of how we use your data). Please note: if you opt out of these cookies and trackers, your web experience may be severely degraded.

Only your physician will have access to your results. For more information about this and other privacy-related questions, please refer to our Privacy Policy.